

PRESS RELEASE

Er-Kim and AFYX Therapeutics A/S announces distribution and sales collaboration

Hørsholm, Denmark – 6th January 2025 - Er-Kim and AFYX Therapeutics A/S announced today a distribution and sales collaboration for two AFYX products. The two companies have entered a mutual sales and distribution collaboration where Er-Kim will sell and distribute the two AFYX products, Gefena and Nimox, to the following countries: Albania, Bosnia & Herzegovina, Bulgaria, Croatia, Cyprus, Czechia, Estonia, Greece, Hungary, Latvia, Lithuania, Malta, Moldova, Montenegro, North Macedonia, Poland, Romania, Serbia, Slovakia, Slovenia, Turkey and Ukraine. Both products are expected to obtain EU regulatory approvals during 2025 and 2026.

Gefena is intended for induction of labor in pregnant women who are beyond their scheduled day of labor. Nimox is a hypoxic radiosensitizer that has been shown to improve the effect of radiation in head and neck cancer patients.

Claus Møller-San Pedro
CEO & Founder

About Er-Kim and AFYX

Er-Kim broadens and accelerates global patient access to innovative treatments by offering biopharmaceutical companies of all sizes flexible, sustainable, and compelling business models to commercialize their products in international markets. Over the past forty years, more than sixty global pharmaceutical companies trusted Er-Kim as their regional partner. For more information: <https://www.er-kim.com>

At AFYX - Reversed Innovation is our core value.

As a leader in the biopharmaceutical industry, reversed innovation aligns with our broader theme, as we take an existing product or technology and use it to address a new or previously overlooked or unconsidered medical problem or condition. For more information: <https://afytx.com>

For more information please contact: Helle Heidensleben;
hh@afytx.com; +453162 7798